Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement only “as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.”
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of RYSTIGGO (rozanolixizumab) is substantial only as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adultpatients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.
|
See also
HAS opinions and decisions
03/05/2024
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
Ke27nSVcf6w8tBVV
